Masimo Co. (NASDAQ:MASI) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 5.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 370,028 shares of the medical equipment provider's stock after selling 23,260 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.69% of Masimo worth $49,336,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in MASI. NBC Securities Inc. grew its position in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 73 shares during the period. GAMMA Investing LLC grew its holdings in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 200 shares in the last quarter. Lazard Asset Management LLC lifted its holdings in Masimo by 5,730.0% in the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 573 shares during the period. Finally, HHM Wealth Advisors LLC boosted its position in Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock worth $79,000 after purchasing an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Price Performance

Masimo stock traded up $1.65 during midday trading on Friday, reaching $172.54. The company had a trading volume of 240,979 shares, compared to its average volume of 680,424. Masimo Co. has a 12-month low of $91.60 and a 12-month high of $178.27. The firm's fifty day simple moving average is $149.24 and its 200-day simple moving average is $129.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market capitalization of $9.24 billion, a P/E ratio of 118.99 and a beta of 0.97.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same quarter last year, the business posted $0.63 earnings per share. The business's quarterly revenue was up 5.4% compared to the same quarter last year. As a group, equities analysts anticipate that Masimo Co. will post 4.03 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on MASI. Stifel Nicolaus reiterated a "buy" rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James upgraded shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price objective for the company in a research report on Wednesday, November 6th. BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Piper Sandler upped their price target on Masimo from $165.00 to $180.00 and gave the stock an "overweight" rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $167.00.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.